Safety of percutaneous renal cryoablation: an international multicentre experience from the EuRECA retrospective percutaneous database.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 13 11 2018
accepted: 20 03 2019
revised: 05 01 2019
pubmed: 17 4 2019
medline: 15 1 2020
entrez: 17 4 2019
Statut: ppublish

Résumé

To investigate the safety profile of percutaneous cryoablation of renal tumours < 7 cm, utilising data extracted from an international multicentre registry. A retrospective review of all immediate and delayed complications from a multicentre database was performed and was categorised according to the Clavien-Dindo classification. Statistical analysis was performed for both overall complications (all Clavien-Dindo) and major complications (Clavien-Dindo 3 to 5). The following criteria were identified as potential predictive factors for complications: centre number, modality of image guidance, tumour size (≤ 4 cm vs. > 4 cm), number of tumours treated in the same session (1 vs. > 1) and tumour histology. A total of 713 renal tumours underwent ablation in 647 individual sessions. In 596 of the cases, one tumour was treated; in the remaining 51 cases, several tumours were treated per session. Mean lesion size was 2.8 cm. Fifty-four complications (Clavien-Dindo 1 to 5) occurred as a result of the 647 procedures, corresponding to an overall complication rate of 8.3%. The most frequent complication was bleeding (3.2%), with 9 cases (1.4%) requiring subsequent treatment. The rate of major complication was 3.4%. The only statistically significant prognostic factor for a major complication was a tumour size > 4 cm. Percutaneous renal cryoablation is associated with a low rate of complications. Tumours measuring more than 4 cm are associated with a higher risk of major complications. • Percutaneous kidney cryoablation has a low rate of complications. • Bleeding is the most frequent complication. • A tumour size superior to 4 cm is a predictive factor of major complication.

Identifiants

pubmed: 30989346
doi: 10.1007/s00330-019-06191-y
pii: 10.1007/s00330-019-06191-y
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

6293-6299

Références

Eur Urol. 2015 Feb;67(2):252-9
pubmed: 25108580
Cardiovasc Intervent Radiol. 2016 Nov;39(11):1604-1610
pubmed: 27435583
Cryobiology. 1998 Nov;37(3):171-86
pubmed: 9787063
Cardiovasc Intervent Radiol. 2017 Feb;40(2):177-191
pubmed: 27987000
BJU Int. 2014 Mar;113(3):416-28
pubmed: 24053769
Insights Imaging. 2017 Jun;8(3):357-363
pubmed: 28500486
Cardiovasc Intervent Radiol. 2014 Dec;37(6):1494-9
pubmed: 24385225
Invest Urol. 1976 Nov;14(3):241-5
pubmed: 992978
Eur Radiol. 2012 Nov;22(11):2547-52
pubmed: 22660984
BJU Int. 2013 Oct;112(6):758-65
pubmed: 23581293
J Vasc Interv Radiol. 2018 Feb;29(2):285-290
pubmed: 29414197
BJU Int. 2017 Mar;119(3):390-395
pubmed: 27488479
J Radiol. 2011 Sep;92(9):774-88
pubmed: 21944236
Abdom Radiol (NY). 2016 Apr;41(4):754-66
pubmed: 26915090
J Vasc Interv Radiol. 2018 Jan;29(1):18-29
pubmed: 29102464
J Vasc Interv Radiol. 2012 Jan;23(1):48-54
pubmed: 22037491
Turk J Urol. 2018 Mar;44(2):142-147
pubmed: 29511584
Cryobiology. 2018 Aug;83:90-94
pubmed: 29890126
Cardiovasc Intervent Radiol. 2013 Jun;36(3):783-90
pubmed: 22933102
J Vasc Interv Radiol. 2018 Aug;29(8):1122-1126
pubmed: 29887184
Radiology. 2018 Nov;289(2):554-561
pubmed: 30084744
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Cryobiology. 2007 Dec;55(3):189-99
pubmed: 17888898
Radiology. 2014 Sep;272(3):903-10
pubmed: 24814178
AJR Am J Roentgenol. 2013 Dec;201(6):1353-61
pubmed: 24261377
J Endourol. 2010 Aug;24(8):1255-62
pubmed: 20380510
Eur Radiol. 2019 Mar;29(3):1293-1307
pubmed: 30255245
Urol Oncol. 2013 Jul;31(5):686-92
pubmed: 21723752
Eur J Radiol. 2018 Mar;100:14-22
pubmed: 29496072

Auteurs

J Garnon (J)

Department of Interventional Radiology, Nouvel Hôpital Civil, 1, place de l'hôpital, 67096, Strasbourg Cedex, France. juliengarnon@gmail.com.

M J Van Strijen (MJ)

Department of Radiology, St. Antonius Hospital, Niewegein, the Netherlands.

T K Nielsen (TK)

Department of Urology, Aarhus University Hospital, Aarhus, Denmark.

A J King (AJ)

Department of Radiology, University Hospital Southampton NHS Trust, Tremona Road, Southampton, SO16 6YD, UK.

A D Montauban Van Swijndregt (AD)

Department of Urology, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1091 AC, Amsterdam, Netherlands.

R L Cazzato (RL)

Department of Interventional Radiology, Nouvel Hôpital Civil, 1, place de l'hôpital, 67096, Strasbourg Cedex, France.

P Auloge (P)

Department of Interventional Radiology, Nouvel Hôpital Civil, 1, place de l'hôpital, 67096, Strasbourg Cedex, France.

C Rousseau (C)

Clinical Investigation Center INSERM 1414, University Hospital of Rennes and University of Rennes, Rennes, France.

D Dalili (D)

Department of Radiology, Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, UK.

F X Keeley (FX)

Department of Urology, Bristol Urological Institute, Bristol, UK.

B W Lagerveld (BW)

Department of Urology, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1091 AC, Amsterdam, Netherlands.

D J Breen (DJ)

Department of Radiology, University Hospital Southampton NHS Trust, Tremona Road, Southampton, SO16 6YD, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH